AIM: Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis and/or gestational morbidity in patients with antiphospholipid autoantibodies (aPL). Over recent years, IgA anti-beta2-glycoprotein I (B2GPI) antibodies (IgA aB2GPI) have reached similar clinical relevance as IgG or IgM isotypes. We recently described the presence of immune complexes of IgA bounded to B2GPI (B2A-CIC) in the blood of patients with antecedents of APS symptomalology. However, B2A-CIC's clinical associations with thrombotic events (TEV) have not been described yet. METHODS: A total of 145 individuals who were isolate positive for IgA aB2GPI were studied: 50 controls without any APS antecedent, 22 patients with recent TEV (Group-1), and 73 patients with antecedents of old TEV (Group-2). RESULTS: Mean B2A-CIC levels and prevalence in Group-1 were 29.6±4.1 AU and 81.8%, respectively, and were significantly higher than those of Group-2 and controls (p＜0.001). In a multivariable analysis, positivity of B2A-CIC was an independent variable for acute thrombosis with a 22.7 odd ratio (confidence interval 5.1-101.6, 95%, p＜0.001). Levels of B2A-CIC dropped significantly two months after the TEV. B2A-CIC positive patients had lower platelet levels than B2A-CIC-negative patients (p＜0.001) and more prevalence of thrombocytopenia (p＜0.019). Group-1 had no significant differences in C3 and C4 levels compared with other groups. CONCLUSION: B2A-CIC is strongly associated with acute TEV. Patients who did not develop thrombosis and were B2A-CIC positive had lower platelet levels, which suggest a hypercoagulable state. This mechanism is unrelated to complement-fixing aPL. B2A-CIC could potentially select IgA aB2GPI-positive patients at risk of developing a thrombotic event.
AIM: Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis and/or gestational morbidity in patients with antiphospholipid autoantibodies (aPL). Over recent years, IgA anti-beta2-glycoprotein I (B2GPI) antibodies (IgA aB2GPI) have reached similar clinical relevance as IgG or IgM isotypes. We recently described the presence of immune complexes of IgA bounded to B2GPI (B2A-CIC) in the blood of patients with antecedents of APS symptomalology. However, B2A-CIC's clinical associations with thrombotic events (TEV) have not been described yet. METHODS: A total of 145 individuals who were isolate positive for IgA aB2GPI were studied: 50 controls without any APS antecedent, 22 patients with recent TEV (Group-1), and 73 patients with antecedents of old TEV (Group-2). RESULTS: Mean B2A-CIC levels and prevalence in Group-1 were 29.6±4.1 AU and 81.8%, respectively, and were significantly higher than those of Group-2 and controls (p＜0.001). In a multivariable analysis, positivity of B2A-CIC was an independent variable for acute thrombosis with a 22.7 odd ratio (confidence interval 5.1-101.6, 95%, p＜0.001). Levels of B2A-CIC dropped significantly two months after the TEV. B2A-CIC positive patients had lower platelet levels than B2A-CIC-negative patients (p＜0.001) and more prevalence of thrombocytopenia (p＜0.019). Group-1 had no significant differences in C3 and C4 levels compared with other groups. CONCLUSION: B2A-CIC is strongly associated with acute TEV. Patients who did not develop thrombosis and were B2A-CIC positive had lower platelet levels, which suggest a hypercoagulable state. This mechanism is unrelated to complement-fixing aPL. B2A-CIC could potentially select IgA aB2GPI-positive patients at risk of developing a thrombotic event.
Authors: Antonio Serrano; Florencio García; Manuel Serrano; Elisa Ramírez; F Javier Alfaro; David Lora; Agustín Gómez de la Cámara; Estela Paz-Artal; Manuel Praga; Jose M Morales Journal: Kidney Int Date: 2012-02-22 Impact factor: 10.612
Authors: Laura Andreoli; Cecilia B Chighizola; Cecilia Nalli; Maria Gerosa; M Orietta Borghi; Francesca Pregnolato; Claudia Grossi; Alessandra Zanola; Flavio Allegri; Gary L Norman; Michael Mahler; Pier Luigi Meroni; Angela Tincani Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995
Authors: Manuel Serrano; Jose Angel Martínez-Flores; Maria José Castro; Florencio García; David Lora; Dolores Pérez; Esther Gonzalez; Estela Paz-Artal; Jose M Morales; Antonio Serrano Journal: J Immunol Res Date: 2014-04-10 Impact factor: 4.818
Authors: Jose M Morales; Manuel Serrano; Jose Angel Martinez-Flores; Fracisco Javier Gainza; Roberto Marcen; Manuel Arias; Fernando Escuin; Dolores Pérez; Amado Andres; Miguel Angel Martínez; Naroa Maruri; Eva Alvarez; José Luis Castañer; Marcos López-Hoyos; Antonio Serrano Journal: Front Immunol Date: 2018-03-12 Impact factor: 7.561
Authors: Manuel Serrano; Laura Morán; Jose Angel Martinez-Flores; Esther Mancebo; Daniel Pleguezuelo; Oscar Cabrera-Marante; Juan Delgado; Antonio Serrano Journal: Front Immunol Date: 2019-12-23 Impact factor: 7.561
Authors: Daniel E Pleguezuelo; Raquel Díaz-Simón; Oscar Cabrera-Marante; Antonio Lalueza; Estela Paz-Artal; Carlos Lumbreras; Antonio Serrano Hernández Journal: Front Immunol Date: 2021-04-12 Impact factor: 7.561
Authors: Carlos Tortosa; Oscar Cabrera-Marante; Manuel Serrano; José A Martínez-Flores; Dolores Pérez; David Lora; Luis Morillas; Estela Paz-Artal; José M Morales; Daniel Pleguezuelo; Antonio Serrano Journal: PLoS One Date: 2017-07-20 Impact factor: 3.240